| Name | Title | Contact Details |
|---|
Prolonging Life and Enhancing its Quality Technology to improve the health of your immune system Learn more about our technology AditxtScore™ AditxtReprogramming™ AditxtScore™
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry`s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma`s current portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson`s Imbruvica, Astellas` and Pfizer`s Xtandi, Biogen`s Tysabri, Johnson & Johnson`s Tremfya, Gilead`s Trodelvy, Merck`s Januvia, Novartis` Promacta, Vertex`s Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates.
Taylor Technology is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Celator Pharmaceuticals is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ibis Biosciences a Division of Abbott is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.